Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency in the activity of the lysosomal hydrolase α-galactosidase A (α-gal). This deficiency results in accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in lysosomes. Endothelial cell storage of GL-3 frequently leads to kidney dysfunction, cardiac and cerebrovascular disease. The current treatment for Fabry disease is through infusions of recombinant α-gal (enzyme-replacement therapy; ERT). Although ERT can markedly reduce the lysosomal burden of GL-3 in endothelial cells, variability is seen in the clearance from several other cell types. This suggests that alternative and adjuvant therapies may be desirable. Use of glucosylceramide synthase inhibitors to abate the biosynthesis of glycosphingolipids (substrate reduction therapy, SRT) has been shown to be effective at reducing substrate levels in the related glycosphingolipidosis, Gaucher disease. Here, we show that such an inhibitor (eliglustat tartrate, Genz-112638) was effective at lowering GL-3 accumulation in a mouse model of Fabry disease. Relative efficacy of SRT and ERT at reducing GL-3 levels in Fabry mouse tissues differed with SRT being more effective in the kidney, and ERT more efficacious in the heart and liver. Combination therapy with ERT and SRT provided the most complete clearance of GL-3 from all the tissues. Furthermore, treatment normalized urine volume and uromodulin levels and significantly delayed the loss of a nociceptive response. The differential efficacies of SRT and ERT in the different tissues indicate that the combination approach is both additive and complementary suggesting the possibility of an improved therapeutic paradigm in the management of Fabry disease.
Applied Discovery Research, Genzyme Corporation, Framingham, Massachusetts, USA. john.marshall@genzyme.com
John
J
Marshall
Karen M
KM
Ashe
Dinesh
D
Bangari
KerryAnne
K
McEachern
Wei-Lien
WL
Chuang
Joshua
J
Pacheco
Diane P
DP
Copeland
Robert J
RJ
Desnick
James A
JA
Shayman
Ronald K
RK
Scheule
Seng H
SH
Cheng
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D056947:Enzyme Replacement Therapy / Q000379:methods*; D000795:Fabry Disease / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D005260:Female; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D057507:Mice, 129 Strain; D018345:Mice, Knockout; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014281:Trihexosylceramides / Q000378:metabolism / Q000652:urine; D058949:Uromodulin / Q000652:urine; D000519:alpha-Galactosidase / Q000235:genetics / Q000627:therapeutic use*
D011759:Pyrrolidines; D014281:Trihexosylceramides; D058949:Uromodulin; C018549:globotriaosylceramide; C522917:eliglustat; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase; D000519:alpha-Galactosidase